<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02032004</url>
  </required_header>
  <id_info>
    <org_study_id>MSB-MPC-CHF001</org_study_id>
    <nct_id>NCT02032004</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) for the Treatment of Heart Failure.</brief_title>
  <acronym>DREAM HF-1</acronym>
  <official_title>Double-blind, Randomized, Sham-procedure-controlled, Parallel-Group Efficacy and Safety Study of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) in Chronic Heart Failure Due to LV Systolic Dysfunction (Ischemic or Nonischemic) Dream HF-1</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mesoblast, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mesoblast, Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to determine whether transendocardial delivery of
      allogeneic human bone marrow-derived MPCs (rexlemestrocel-L) is effective in the treatment of
      chronic heart failure due to LV systolic dysfunction.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of a single transendocardial
      delivery in the cardiac catheterization laboratory of human bone marrow-derived allogeneic
      MPCs (rexlemestrocel-L) for improvement in clinical outcomes (HF-MACE), preventing further
      adverse cardiac remodeling (LVESV and LVEDV), and increasing exercise capacity (6MWT) in
      patients with chronic HF due to LV systolic dysfunction of either ischemic or nonischemic
      etiology who have received optimal medical/revascularization therapy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2014</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to non-fatal recurrent decompensated heart failure (HF) events in the presence of terminal HF-related major adverse cardiac events (HF-MACE)</measure>
    <time_frame>12 Month minimum</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total hospital admissions for non-fatal recurrent decompensated HF events</measure>
    <time_frame>12 Month minimum</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total hospital admissions or urgent HF visits for non-fatal decompensated HF</measure>
    <time_frame>12 Month minimum</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of in-hospital stay in intensive care unit for decompensated HF</measure>
    <time_frame>12 Month minimum</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of non-fatal recurrent decompensated HF events resulting in hospitalization or urgent HF visits hospitalization or urgent HF visits</measure>
    <time_frame>12 Month minimum</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac survival (captures only cardiac deaths)</measure>
    <time_frame>12 Month minimum</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (captures all cause deaths)</measure>
    <time_frame>12 Month minimum</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time-to-first HF-MACE</measure>
    <time_frame>12 Month minimum</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time-to-death from cardiovascular causes</measure>
    <time_frame>12 Month minimum</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left Ventricular remodeling in LVESV determined by 2-D echocardiography</measure>
    <time_frame>Baseline, months 3, 6, 12 and every 12 months thereafter until study conclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LV remodeling in LVEDV determined by 2-D echocardiography</measure>
    <time_frame>Baseline, months 3, 6, 12 and every 12 months thereafter until study conclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Left Ventricular systolic performance performance as assessed by LVEF (RVG or echocardiogram)</measure>
    <time_frame>Baseline and months 3, 6, 12 and every 12 months thereafter until study conclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional exercise capacity as assessed by 6 Minute Walk Test</measure>
    <time_frame>Baseline, months 3, 6, 12 and every 12 months thereafter until study conclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional status by New York Heart Association (NYHA) class</measure>
    <time_frame>Baseline, months 3, 6, 12 and every 12 months thereafter until study conclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Measure - Minnesota Living With Heart Failure (MLHF) questionnaire</measure>
    <time_frame>Baseline, months 3, 6, 12 and every 12 months thereafter until study conclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Measure - EuroQoL 5-dimensional (EQ-5D) questionnaire</measure>
    <time_frame>Baseline, months 3, 6, 12 and every 12 months thereafter until study conclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time-to-terminal HF-MACE</measure>
    <time_frame>12 Month minimum</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of rexlemestrocel-L will be assessed throughout the study</measure>
    <time_frame>12 Month minimum</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics Studies Measures</measure>
    <time_frame>Baseline, months 3, 6, 12 and every 12 months thereafter until study conclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacogenomics (PGx) Analysis</measure>
    <time_frame>Screening</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity Measures</measure>
    <time_frame>Baseline, day 10, months 1, 3, 6, and 12, and every 6 months during study conduct</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exploratory Measures</measure>
    <time_frame>Protocol specified time points during the course of the study</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Chronic Heart Failure</condition>
  <arm_group>
    <arm_group_label>Allogeneic Mesenchymal Precursor Cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants randomly assigned to treatment will undergo a single index cardiac catheterization involving transendocardial delivery of rexlemestrocel-L into the myocardium at a cell injection center by an interventional cardiology team not involved with review or assessment of subsequent study results.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Treatment</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Participants randomly assigned to control treatment will undergo a single cardiac catheterization involving a scripted sham cardiac mapping and cell delivery procedure at a cell injection center by an interventional cardiology team not involved with review or assessment of subsequent study results.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Allogeneic Mesenchymal Precursor Cells (MPC)</intervention_name>
    <description>Rexlemestrolcel-L consists of human bone marrow-derived allogeneic MPCs isolated from bone mononuclear cells with anti-STRO-3 antibodies, expanded ex vivo,and cryopreserved</description>
    <arm_group_label>Allogeneic Mesenchymal Precursor Cells</arm_group_label>
    <other_name>MPC</other_name>
    <other_name>rexlemestrocel-L</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sham Comparator</intervention_name>
    <description>The sham procedure will be staged to script and will not include actual cardiac mapping or delivery of rexlemestrocel-L.</description>
    <arm_group_label>Control Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The patient is 18 to 80 years of age, inclusive; both men and women will be enrolled.

          -  The patient has a diagnosis of chronic HF of ischemic or nonischemic etiology for at
             least 6 months

          -  The patient is on stable, optimally tolerated dosages of HF therapies including
             beta-blockers (approved for country-specific usage), angiotensin-converting enzyme
             (ACE) inhibitors or angiotensin-receptor blockers (ARBs), and/or aldosterone
             antagonists, without change in dose for at least 1 month before study intervention

          -  The patient is on a stable, outpatient, oral diuretic dosing regimen in which the
             patient remains clinically stable during screening.

          -  Other Criteria apply, please contact the investigator

        Exclusion Criteria:

          -  The patient has NYHA Functional Class I or Functional Class IV symptoms.

          -  Other Criteria apply, please contact the investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Donna Skerrett, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Mesoblast, Ltd.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Syneos Health</last_name>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Aimee Barrera, Associate Project Director</last_name>
    <phone>+1 919 602 5311</phone>
    <email>aimee.barrera@syneoshealth.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mesoblast Investigational Site 10757 - Cardiology, P.C.</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan DeRamus</last_name>
      <email>sderamus@cardiologypc.com</email>
    </contact>
    <investigator>
      <last_name>Alain Bouchard, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mesoblast Investigational Site 13262 - University of Alabama at Birmingham Hospital</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brittany Johnson</last_name>
      <email>bejohnson@uabmc.edu</email>
    </contact>
    <investigator>
      <last_name>Sumanth Prabhu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mesoblast Investigational Site 10779 - Mercy Gilbert Medical Center</name>
      <address>
        <city>Gilbert</city>
        <state>Arizona</state>
        <zip>85297</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brian Mutoff</last_name>
      <email>Brian.Mutoff@dignityhealth.org</email>
    </contact>
    <investigator>
      <last_name>Anantharam Kalya, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mesoblast Investigational Site 10786 - Cardiovascular Associates of Mesa</name>
      <address>
        <city>Mesa</city>
        <state>Arizona</state>
        <zip>85206</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vonnie Fuentes</last_name>
      <email>sfuentes@cvam.com</email>
    </contact>
    <investigator>
      <last_name>Andrew Kaplan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mesoblast Investigational Site 10756 - Mayo Clinic</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Megan Kelly</last_name>
      <email>Kelly.Megan1@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Robert Scott, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mesoblast Investigational Site 13023 - University of Arizona Medical Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine MacDonald</last_name>
      <email>Cmacdonald@shc.arizona.edu</email>
    </contact>
    <investigator>
      <last_name>Ranjith Shetty, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mesoblast Investigational Site 10754 - University of California, San Diego</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melanee Schimmel</last_name>
      <email>mschimmel@ucsd.edu</email>
    </contact>
    <investigator>
      <last_name>Eric Adler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mesoblast Investigational Site 10759 - Scripps Clinic</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heather Catchpole</last_name>
      <email>Catchpole.Heather@scrippshealth.org</email>
    </contact>
    <investigator>
      <last_name>James Heywood, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mesoblast Investigational Site 13265 - University of California, Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ladda Douangvila</last_name>
      <email>ldouangvila@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Ali Nsair, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mesoblast Investigational Site 10775 - Cedars-Sinai Medical Care Foundation</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Thottam</last_name>
      <email>Maria.Thottam@cshs.org</email>
    </contact>
    <investigator>
      <last_name>David Chang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mesoblast Investigational Site 10778 - Orange County Cardiology</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karena De La Mora</last_name>
      <email>kdelamora@ocheartinstitute.com</email>
    </contact>
    <investigator>
      <last_name>Kelly Tucker, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mesoblast Investigational Site 13031 - St. John's Regional Medical Center</name>
      <address>
        <city>Oxnard</city>
        <state>California</state>
        <zip>93030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lindsey McFarland</last_name>
      <email>Lindsey.McFarland@DignityHealth.org</email>
    </contact>
    <investigator>
      <last_name>Richard Rothschild, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mesoblast Investigational Site 13275 - Stanford University Hospital</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Divya Rajmohan</last_name>
      <email>rajmohan@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Phillip Yang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mesoblast Investigational Site 13267 - Bethesda Heart Hospital</name>
      <address>
        <city>Boynton Beach</city>
        <state>Florida</state>
        <zip>33435</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Marquez</last_name>
      <email>emarquez@rpna.net</email>
    </contact>
    <investigator>
      <last_name>Christina Michael, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mesoblast Investigational Site 10780 - Morton Plant Hospital</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33756</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Terri Jones</last_name>
      <email>teresa.jones@baycare.org</email>
    </contact>
    <investigator>
      <last_name>Leslie Miller, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mesoblast Investigational Site 10760 - Shands Hospital, University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicole Bostick</last_name>
      <email>Janette.bostick@medicine.ufl.edu</email>
    </contact>
    <contact_backup>
      <last_name>Kasey Smith</last_name>
      <email>Kasey.smith@medicine.ufl.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Carl Pepine, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mesoblast Investigational Site 13273 - University of Florida Health</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chauncey Smoot</last_name>
      <email>Chauncey.Smoot@jax.ufl.edu</email>
    </contact>
    <investigator>
      <last_name>Francesco Franchi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mesoblast Investigational Site 10768 - University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinators</last_name>
      <email>ISCISStudyInfo@miami.edu</email>
    </contact>
    <investigator>
      <last_name>Sandra Chaparro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mesoblast Investigational Site 13280</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Aimee Barrera</last_name>
      <email>aimee.barrera@syneoshealth.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mesoblast Investigational Site 13264 - Florida Hospital Pepin Heart Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33613</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Szymanski</last_name>
      <email>Elizabeth.Szymanski@ahss.org</email>
    </contact>
    <investigator>
      <last_name>Mohammadreza Tabesh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mesoblast Investigational Site 13027 - Emory University School of Medicine</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sher Shalman</last_name>
      <email>ssher2@emory.edu</email>
    </contact>
    <investigator>
      <last_name>David Markham, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mesoblast Investigational Site 10765 - Georgia Regents University</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sara Smith</last_name>
      <email>SHOPKINS@augusta.edu</email>
    </contact>
    <contact_backup>
      <last_name>Carol Smith</last_name>
      <email>CSMITH@augusta.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Neal Weintraub, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mesoblast Investigational Site 10772 - University Cardiologist, Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nusrat Jahan</last_name>
      <email>Nusrat_Jahan@rush.edu</email>
    </contact>
    <investigator>
      <last_name>Dinesh Kalra, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mesoblast Investigational Site 13030 - University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cynthia Larew</last_name>
      <email>Cynthia-larew@uiowa.edu</email>
    </contact>
    <investigator>
      <last_name>Linda Cadaret, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mesoblast Investigational Site 10783 - Gill Heart Institute, University of Kentucky</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura True</last_name>
      <email>lauratrue@uky.edu</email>
    </contact>
    <investigator>
      <last_name>Ahmed Abdel-Latif, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mesoblast Investigational Site 13022 - University of Louisville</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Marie Webb</last_name>
      <email>anne.webb@louisville.edu</email>
    </contact>
    <investigator>
      <last_name>Emma Birks, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mesoblast Investigational Site 13266</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Mesoblast Investigational Site 10782</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mesoblast Investigational Site 13029</name>
      <address>
        <city>Haverhill</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Mesoblast Investigational Site 10766 - Michigan Cardiovascular Institute</name>
      <address>
        <city>Saginaw</city>
        <state>Michigan</state>
        <zip>48602</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Val Bitzer</last_name>
      <email>Valerie.bitzer@ascension.org</email>
    </contact>
    <investigator>
      <last_name>Peter Fattal, MD, FACC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mesoblast Investigational Site 10762 - Minneapolis Heart Institute</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jane Fox</last_name>
      <email>jane.fox@allina.com</email>
    </contact>
    <investigator>
      <last_name>Mosi Bennett, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mesoblast Investigational Site 10761 - Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Barry Borlaug</last_name>
      <email>Borlaug.Barry@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Barry Borlaug, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mesoblast Investigational Site 13281</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Aimee Barrera</last_name>
      <email>aimee.barrera@syneoshealth.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mesoblast Investigational Site 13263 - RWJ Barnabas Heart Center</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Saurabh Kapoor</last_name>
      <email>Saurabh.kapoor@rwjbh.org</email>
    </contact>
    <contact_backup>
      <last_name>Dr. Mark Zucker</last_name>
      <email>Mark.zucker@rwjbh.org</email>
    </contact_backup>
    <investigator>
      <last_name>Saurabh Kapoor, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mesoblast Investigational Site 10776 - Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Danielle Brunjes, PhD</last_name>
      <email>caccresearch@cumc.columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Maryjane Farr, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mesoblast Investigational Site 13026 - Sanger Heart and Vascular Institute, Carolinas Healthcare System</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan McClain</last_name>
      <email>Susan.mcclain@AtriumHealth.org</email>
    </contact>
    <investigator>
      <last_name>Joseph Mishkin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mesoblast Investigational Site 10781 - Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexis Sharp</last_name>
      <email>alexis.sharp@duke.edu</email>
    </contact>
    <investigator>
      <last_name>Thomas Povsic, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mesoblast Investigational Site 10758 - The Christ Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Ibanez</last_name>
      <email>karen.ibanez@thechristhospital.com</email>
    </contact>
    <investigator>
      <last_name>Eugene Chung, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mesoblast Investigational Site 10770 - University of Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carol Knochelman</last_name>
      <email>knochecl@UCMAIL.UD.EDU</email>
    </contact>
    <investigator>
      <last_name>Vlad Cotarlan, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mesoblast Investigational Site 10773</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Mesoblast Investigational Site 13278 - OhioHealth Research Institute</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43214</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kitra Hunter</last_name>
      <email>Kitra.Hunter@Ohiohealth.com</email>
    </contact>
    <investigator>
      <last_name>Anupam Basuray, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mesoblast Investigational Site 10785 - Lehigh Valley Hospital</name>
      <address>
        <city>Allentown</city>
        <state>Pennsylvania</state>
        <zip>18103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristen Cornell</last_name>
      <email>Kristen.Cornell@lvhn.org</email>
    </contact>
    <investigator>
      <last_name>Ronald Freudenberger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mesoblast Investigational Site 13261 - University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia DiVito</last_name>
      <email>Patricia.Divito@uphs.upenn.edu</email>
    </contact>
    <investigator>
      <last_name>Brian Drachman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mesoblast Investigational Site 10767 - Temple University Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Rene J. Alvarez, Jr.</last_name>
      <email>rene.alvarez@tuhs.temple.edu</email>
    </contact>
    <investigator>
      <last_name>Rene Alvarez, Jr., MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mesoblast Investigational Site 13277</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Aimee Barrera</last_name>
      <email>aimee.barrera@syneoshealth.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mesoblast Investigational Site 10774 - University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Mark Simon</last_name>
      <email>simonma@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>Marc Simon, MD, MS, FACC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mesoblast Investigational Site 10777 - Stern Cardiovascular Foundation</name>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <zip>38125</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brian Dragutsky</last_name>
      <email>bdrag@sterncardio.com</email>
    </contact>
    <investigator>
      <last_name>Frank McGrew, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mesoblast Investigational Site 13024 - Austin Heart, PLLC</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78756</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lorie Tibbits</last_name>
      <email>ltibbits@austinheart.com</email>
    </contact>
    <investigator>
      <last_name>Roger Gammon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mesoblast Investigational Site 13274 - Soltero CV Research Center, Baylor Scott &amp; White Research Institute</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pamela Coker</last_name>
      <email>Pamela.Coker@BSWHealth.org</email>
    </contact>
    <investigator>
      <last_name>Cara East, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mesoblast Investigational Site 13028</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Mesoblast Investigational Site 10755 - Texas Heart Institute</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sara Sampaio</last_name>
      <email>ssampaio@texasheart.com</email>
    </contact>
    <investigator>
      <last_name>Emerson Perin, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mesoblast Investigational Site 13268 - Houston Methodist Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohamad G. Ghosn</last_name>
      <email>mghosn@houstonmethodist.org</email>
    </contact>
    <investigator>
      <last_name>Barry Trachtenberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mesoblast Investigational Site 10763 - University Hospital</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlyn Sander</last_name>
      <email>Carlyn.sander@hsc.utah.edu</email>
    </contact>
    <investigator>
      <last_name>Craig Selzman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mesoblast Investigational Site 10771 - Heart &amp; Vascular Research, Swedish Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98122</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charlene Boisjolie</last_name>
      <email>charlene.boisjolie@swedish.org</email>
    </contact>
    <investigator>
      <last_name>John Petersen II, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mesoblast Investigational Site 10788</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Mesoblast Investigational Site 10764 - University of Wisconsin</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leslie Gilbert</last_name>
      <email>lgilbert@medicine.wisc.edu</email>
    </contact>
    <investigator>
      <last_name>David Murray, MD, FACC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mesoblast Investigational Site 10769 - Aurora Healthcare</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Don Lobacz</last_name>
      <email>donald.lobacz@aurora.org</email>
    </contact>
    <investigator>
      <last_name>Nasir Sulemanjee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mesoblast Investigational Site 13279</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Aimee Barrera</last_name>
      <email>aimee.barrera@syneoshealth.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mesoblast Investigational Site 10789 - Aspirus Research Institute</name>
      <address>
        <city>Wausau</city>
        <state>Wisconsin</state>
        <zip>54401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Megan Johnson</last_name>
      <email>Megan.Johnson@aspirus.org</email>
    </contact>
    <investigator>
      <last_name>German Larrain, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mesoblast Investigational Site 11027</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Aimee Barrera</last_name>
      <email>aimee.barrera@syneoshealth.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mesoblast Investigational Site 11024 - Victoria Heart Institute Foundation</name>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <zip>V8R 4R2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Noreen Lounsbury</last_name>
      <email>nlounsbury@vhif.org</email>
    </contact>
    <investigator>
      <last_name>Elizabeth Swiggum, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mesoblast Investigational Site 11025 - St. Michael's Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5B 1W8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Krisel Abulencia</last_name>
      <email>AbulenciaMa@smh.ca</email>
    </contact>
    <investigator>
      <last_name>Abdul Al-Hesayen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Austria</country>
    <country>Belarus</country>
    <country>Bulgaria</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Latvia</country>
    <country>Lithuania</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Singapore</country>
    <country>Slovenia</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </removed_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 8, 2014</study_first_submitted>
  <study_first_submitted_qc>January 8, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 9, 2014</study_first_posted>
  <last_update_submitted>May 16, 2018</last_update_submitted>
  <last_update_submitted_qc>May 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Heart Failure</keyword>
  <keyword>CHF</keyword>
  <keyword>Left Ventricular Systolic Dysfunction</keyword>
  <keyword>Ischemic Heart Failure</keyword>
  <keyword>Nonischemic Heart Failure</keyword>
  <keyword>Stem Cells</keyword>
  <keyword>Allogeneic Mesenchymal Precursor Cells</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

